Purpose: There is a lack of available evidence regarding the treatment pattern of switches and add-ons for individuals aged 65 years or older with epilepsy during the first years from the time they received their first anti-seizure medication because of the lack of valid methods. Therefore, this study aimed to develop an algorithm for identifying switches and add-ons using secondary data sources for anti-seizure medication users.Methods: Danish nationwide databases were used as data sources. Residents in Denmark between 1996 and 2018 who were diagnosed with epilepsy and redeemed their first prescription for anti-seizure medication after epilepsy diagnosis were followed up for 730 days until the end of the follow-up period, death, or emigration to assess switches and add-ons occurred during the follow-up period. The study outcomes were the overall accuracy of the classification of switch or add-on of the newly developed algorithm.Results: In total, 15870 individuals were included in the study population with a median age of 72.9 years, of whom 52.0% were male and 48.0% were female. A total of 988 of the 15879 patients from the study population were present during the 730-day follow-up period, and 988 individuals (6.2%) underwent a total of 1485 medication events with co-exposure to two or more anti-seizure medications. The newly developed algorithmic method correctly identified 9 out of 10 add-ons (overall accuracy 92%) and 9 out of 10 switches (overall accuracy 88%).Conclusion: The majority of switches and add-ons occurred early during the first 2 years of disease and according to clinical recommendations. The newly developed algorithm correctly identified 9 out of 10 switches/add-ons.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.